10-Q: Pasithea Reports Q2 2025 Loss, Advances Clinical Trials

Pasithea Therapeutics reported a reduced net loss for Q2 2025, driven by clinical trial advancements for PAS-004 and successful capital raises, but faces ongoing liquidity concerns and a Nasdaq minimum bid price deficiency.

Summary

• Net loss for the three months ended June 30, 2025, was $3,716,157, a decrease from $3,866,249 for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $7,279,395, down from $7,727,089 for the six months ended June 30, 2024.
• Basic and diluted loss per share significantly improved to $(0.66) for Q2 2025 from $(3.71) for Q2 2024, and to $(1.85) for the six months ended June 30, 2025, from $(7.41) for the same period in 2024.
• Cash and cash equivalents increased to $7,217,052 as of June 30, 2025, from $6,922,729 at December 31, 2024.
• Working capital increased to $6,899,643 as of June 30, 2025, from $6,248,444 at December 31, 2024.
• Research and development expenses decreased by 9% for the three months and 6% for the six months ended June 30, 2025, primarily due to de-prioritization of discovery programs and workforce reduction, offset by increased clinical trial expenses for PAS-004.
• General and administrative expenses increased by 5% for the three months but decreased by 7% for the six months ended June 30, 2025, driven by shifts in accounting, business development, legal, and public company expenses.
• The company successfully raised approximately $6.3 million in gross proceeds from a May 2025 Public Offering and warrant exercises, and an additional $2.0 million net from an At The Market (ATM) offering during the six months ended June 30, 2025.
• The FIH Phase 1 Dose Escalation Study for PAS-004 completed enrollment and initial dosing of cohort 6, and demonstrated robust target engagement pharmacodynamics results.
• A Phase 1/1b clinical trial for PAS-004 in adult NF1-PN patients was initiated in May 2025, with the first clinical site activated in Australia, and initial dosing of the first cohort completed in July 2025.
• The company received a Nasdaq deficiency notice on June 23, 2025, for not meeting the $1.00 minimum bid price requirement, with a compliance period until December 22, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit going concern warning and the Nasdaq minimum bid price deficiency, which are critical risks. While there was progress in clinical trials and successful capital raises, these are overshadowed by the fundamental financial instability and the immediate threat of delisting. The capital raises are necessary for survival rather than indicative of strong growth.

Positives

• Net loss decreased for both the three and six months ended June 30, 2025, compared to the prior year, indicating improved financial performance.
• Basic and diluted loss per share significantly improved, reflecting a lower loss per share for shareholders.
• Cash and cash equivalents increased by approximately $0.3 million and working capital increased by approximately $0.6 million, strengthening the balance sheet.
• Successful capital raises, including $6.3 million gross from the May 2025 Public Offering and warrant exercises, and $2.0 million net from the ATM agreement, provided crucial funding.
• Progress in the FIH Phase 1 Dose Escalation Study for PAS-004, including completion of cohort 6 enrollment and initial dosing, and demonstration of robust target engagement.
• Initiation of the Phase 1/1b clinical trial for PAS-004 in adult NF1-PN patients and completion of initial dosing for the first cohort, marking significant advancement in the lead product candidate's development.

Negatives

• The company continues to incur significant operating losses and negative cash flows from operations, with an accumulated deficit of approximately $56.9 million as of June 30, 2025.
• Management believes the company will not have sufficient working capital to meet its needs through the next twelve months without raising additional capital, indicating substantial doubt about its ability to continue as a going concern.
• Received a Nasdaq deficiency notice for failing to meet the $1.00 minimum bid price requirement, posing a risk of delisting if compliance is not regained by December 22, 2025.
• Research and development expenses decreased due to de-prioritization of discovery programs and workforce reduction, which could impact future pipeline diversity, despite increased clinical trial spending.
• The company's public float is below $75.0 million, restricting its ability to raise capital through shelf registration statements to one-third of its public float in any twelve-month period.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant operating losses and negative cash flows, requiring additional funding.
• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the $1.00 minimum bid price requirement by December 22, 2025, which could negatively impact stock liquidity and financing ability.
• The development and commercialization of pharmaceutical products are lengthy, expensive, and have uncertain outcomes, with no guarantee of generating product revenue.
• Future funding requirements are substantial and depend on the scope, timing, and results of clinical trials, manufacturing costs, and intellectual property protection.
• Exposure to the impact of inflation, leading to higher costs for employee compensation and outside services, which may not be offset in the near term.
• Dependence on third parties for preclinical and clinical activities, manufacturing, and other services introduces operational risks.
• The company's ability to raise capital through primary public offerings is limited by 'baby shelf rules' due to its public float being less than $75.0 million.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials, and seeks regulatory approval. General and administrative expenses are projected to decrease slightly in fiscal year 2025 compared to 2024 due to reduced legal and public company expenses. Research and development expenses are expected to increase in fiscal year 2025 due to increased clinical research for PAS-004 and manufacturing costs for drug supply, partially offset by reduced preclinical research and workforce reduction. Management believes current working capital is insufficient to meet needs for the next twelve months without additional funding. The company aims to complete the FIH Phase 1 Dose Escalation Study for PAS-004 in 2026 and plans to conduct a Phase 1 trial for pediatric NF1-PN patients, ultimately completing registrational clinical trials in both adult and pediatric NF1-PN populations.

Management Comments

• "We expect general and administrative expenses to decrease slightly throughout fiscal year 2025 as compared to fiscal year 2024 primarily due to reduced legal and public company and corporate communications expenses."
• "We expect research and development expenses to increase throughout fiscal year 2025 as compared to fiscal year 2024 primarily due to (i) an increase in clinical research for PAS-004 related to the ongoing FIH Phase 1 Dose Escalation Study and the Phase 1/1b clinical trial of PAS-004 in adult NF1-PN patients, and (ii) an increase in manufacturing costs related to the drug supply for our clinical trials, offset by decreases in pre-clinical research and the reduction in workforce related to the closure of our research laboratory."
• "Management believes that we will not have sufficient working capital to meet our needs through twelve months from the issuance date of the financial statements included in this Quarterly Report, without raising additional capital."

Industry Context

Pasithea Therapeutics operates in the highly capital-intensive and high-risk clinical-stage biotechnology sector, focusing on CNS disorders, RASopathies, and MAPK pathway-driven tumors. The company's strategy of developing a next-generation MEK inhibitor (PAS-004) aims to address limitations of existing drugs, a common approach in the industry to capture market share. Its progression into Phase 1/1b trials for NF1-PN aligns with a growing focus on rare diseases and targeted therapies. However, like many small biotechs, it faces significant liquidity challenges and reliance on external funding, a common hurdle in bringing novel treatments to market. The Nasdaq minimum bid price deficiency is a frequent challenge for smaller, development-stage companies in this sector, often reflecting market skepticism about long-term viability without consistent positive news or clear paths to profitability.

Comparison to Industry Standards

• NA

Related Party Transactions

• Prof. Lawrence Steinman receives $25,000 per quarter for consulting and advisory services related to clinical and commercial development of product candidates, research and development strategy, and business development efforts.

Stakeholder Impact

• Shareholders face significant risk of investment loss due to the going concern uncertainty and the potential delisting from Nasdaq, which could severely impact stock liquidity and price.
• Employees may face uncertainty regarding job security given the company's ongoing financial losses and dependence on future funding.
• Creditors may face increased risk due to the company's liquidity challenges and reliance on future capital raises.
• Patients and the medical community could benefit from the continued development of PAS-004 for CNS disorders and MAPK pathway-driven tumors, particularly NF1-PN, if clinical trials are successful and funding is secured.

Next Steps

• Complete the FIH Phase 1 Dose Escalation Study for PAS-004 in patients with MAPK pathway-driven advanced tumors in 2026.
• Conduct the Phase 1/1b multicenter, open-label, dose escalation trial of PAS-004 in adult NF1-PN patients at a total of five sites in Australia, South Korea, and the United States.
• Conduct a Phase 1 trial for pediatric NF1-PN patients.
• Complete registrational clinical trials in both adult and pediatric NF1-PN populations for PAS-004.
• Monitor the closing bid price of common stock and consider options, including a potential reverse stock split, to regain compliance with Nasdaq's $1.00 minimum bid price requirement by December 22, 2025.
• Obtain additional working capital funding from the sale of equity and/or debt securities to continue operations.
• Advance discovery stage programs for PAS-003 (ALS) and PAS-001 (schizophrenia).

Key Dates

Recommendation

The company faces severe financial distress, explicitly stating it will not have sufficient working capital for the next 12 months without additional funding, which constitutes a going concern risk. Compounding this, it has received a Nasdaq deficiency notice for failing to meet the minimum bid price, threatening delisting. While clinical trials for PAS-004 are progressing and capital has been raised, these positives are overshadowed by the fundamental instability and the immediate threat to its public listing. The continuous need for capital, coupled with the 'baby shelf rules' limitation, indicates a challenging path forward. For a seasoned investor, the combination of going concern and delisting risk makes this a high-risk, speculative investment with significant downside potential, warranting a strong sell recommendation.

Keywords

Biotechnology, Clinical-stage, CNS disorders, RASopathies, MAPK pathway-driven tumors, MEK inhibitor, PAS-004, Neurofibromatosis type 1, NF1-PN, Clinical trials, Drug development, SEC filing, 10-Q, Nasdaq compliance, Going concern, Capital raise, Biopharma